Case Report
A Jehovah’s Witness with Acute Myeloid Leukemia Successfully Treated with an Epigenetic Drug, Azacitidine: A Clue for Development of Anti-AML Therapy Requiring Minimum Blood Transfusions
Table 1
Azacitidine therapy for AML in the literature.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
aResponse includes CR, partial remission, and hematological improvement defined in the previous report [6]. bPatients were AML with low bone marrow blast counts (blasts 20%–34%). cEight de novo AML and 12 AML transformed from MDS. dPatients were treated with either azacitidine or decitabine and with or without histone deacetylase inhibitor. eTransfusion requirement during the first course of induction chemotherapy was significantly less in patients treated with azacitidine compared with patients treated with conventional anti-AML chemotherapy (RBC transfusions: median 2.7 versus 7 times per month; platelet transfusions: median 0.3 versus 5 times per month). fPatients were treated with either azacitidine or decitabine. |